ARHGEF10
ARHGEF10 (Rho guanine nucleotide exchange factor 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Cutaneous squamous cell carcinoma, Non-small-cell lung cancer and 1 more.
Overview
May play a role in developmental myelination of peripheral nerves.
IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Bladder Urothelial Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ARHGEF10 (Rho guanine nucleotide exchange factor 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Cutaneous squamous cell carcinoma, Non-small-cell lung cancer and 1 more.
- 1 · What it is
ARHGEF10 (Rho guanine nucleotide exchange factor 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Cutaneous squamous cell carcinoma, Non-small-cell lung cancer and 1 more.
- 2 · What goes wrong in cancer
May play a role in developmental myelination of peripheral nerves. Locus 8p23.3 (HGNC).
- 3 · How drugs use it
No product in this corpus aims at ARHGEF10 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:14103 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15013 (protein name, function text, keywords and locations (REST API)); IntOGen ARHGEF10 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
May play a role in developmental myelination of peripheral nerves. Locus 8p23.3 (HGNC).
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Cutaneous squamous cell carcinoma: IntOGen driver in 1 cohort (CSCC)
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (NSCLC)
- Small-cell lung cancer: IntOGen driver in 1 cohort (SCLC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ARHGEF10" OR ABSTRACT:"ARHGEF10" OR TITLE:"Rho guanine nucleotide exchange factor 10" OR ABSTRACT:"Rho guanine nucleotide exchange factor 10" OR TITLE:"KIAA0294" OR ABSTRACT:"KIAA0294" OR TITLE:"Gef10" OR ABSTRACT:"Gef10") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARHGEF10, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetELN
Shares Cutaneous squamous cell carcinoma, IntOGen.
- TrialStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Shares Cutaneous squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Cutaneous squamous cell carcinoma, Non-small-cell lung cancer.
- TrialA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Shares Cutaneous squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TargetCNTRL
Shares Cutaneous squamous cell carcinoma, IntOGen.
- TargetACVR2A
Shares Cutaneous squamous cell carcinoma, IntOGen.
- CompanySummit Therapeutics
Shares Cutaneous squamous cell carcinoma, Non-small-cell lung cancer.
- TreatmentHMBD-001
Shares Cutaneous squamous cell carcinoma, Non-small-cell lung cancer.